Drug Profile

Zabilugene almadenorepvec - Theriva Biologics

Alternative Names: VCN-01

Latest Information Update: 12 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator VCN Biosciences
Developer AstraZeneca; Theriva Biologics; VCN Biosciences
Class Antineoplastics; Eye disorder therapies; Gene therapies; Immunotherapies; Oncolytic viruses
Mechanism of Action Cell death stimulants; Hyaluronidase stimulants; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Retinoblastoma; Adenocarcinoma
New Molecular Entity No

Highest Development Phases

Phase II Adenocarcinoma
Phase I/II Pancreatic cancer; Retinoblastoma; Squamous cell cancer
Phase I Brain cancer; Ovarian cancer
No development reported Solid tumours

Most Recent Events

12 Aug 2026 9472367 - KDM, DC/MOA checked
11 Aug 2026 Biologics License Application for VCN 01 for the treatment of retinoblastoma is approved by the US FDA by September 30, 2029
11 Aug 2026 Theriva Biologics plan to discuss the proposed clinical trial protocol with the US FDA in third quarter of 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com